Richard Mayeux on Field Loses Beloved Wizard of Glia, Ben Barres, 63

COMMENT Ben was a truly remarkable person, who shared his enthusiasm for neuroscience, albeit mostly glia. He made us all question why we were not also investigating glial biology. Ben's generosity in sharing data and information, and his concern for the ...

Richard Mayeux on One Thumb Up on Dietary Fat, One Down on Vitamins, Two Down on Estrogen

COMMENT I basically agree with the conclusions. Intake of vitamin E and C really made little to no difference. The same was true with fat, though we have not yet separated the types of fats. The highest fat intake was among individuals who developed AD. Most ...

Richard Mayeux on Rotterdam Study Questions Links between Fat and Dementia Risk

COMMENT This is a report of a large cohort study finding no association between dietary fat consumption and risk of dementia. The large size and long follow-up of the cohort, and the use of validated measures of dietary intake and diagnosis of dementia support ...

Richard Mayeux on Presenilin-1 regulates the neuronal threshold to excitotoxicity both physiologically and pathologically.

COMMENT This is an important study offering new insights to the mechanisms by with genetic mutations alter the function of proteins such as Presenilin. rpm2 0 ...

Richard Mayeux on The preclinical phase of alzheimer disease: A 22-year prospective study of the Framingham Cohort.

COMMENT This suggests that a "preclinical phase" of Alzheimer's disease exists that precedes the diagnosis by 10 or more years. Others have found that individuals whose memory or other cognitive skills are comparatively weaker than their peers are ...

Richard Mayeux on Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1.

COMMENT Role of PS1/2 as interactive with gamma secretase. rpm2 0 ...

Richard Mayeux on In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease.

COMMENT This study suggests that imaging amyloid plaques may be possible in the future. This would have a significant impact on treatment and diagnosis of AD and related diseases. rpm2 0 ...

Richard Mayeux on Low use of analgesics in Alzheimer's disease: possible mechanisms.

COMMENT Role of PS1/2 investigated with regard to its effect on phospholipids rpm2 0 ...

Richard Mayeux on beta-amyloid (Abeta)42(43), abeta42, abeta40 and apoE immunostaining of plaques in fatal head injury.

COMMENT Excellent study showing the sequence of events with regard to abeta deposition and the role of APOE. rpm2 0 ...

Richard Mayeux on Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state.

COMMENT More on gamma secretase and PS 1. rpm2 0 ...

Richard Mayeux on Effect of anti-inflammatory medications on neuropathological findings in Alzheimer disease.

COMMENT Important study showing little protective effect of anti-inflammatory drugs. rpm2 0 ...

Richard Mayeux on Neuroprotective effects of estrogen against beta-amyloid toxicity are mediated by estrogen receptors in cultured neuronal cells.

COMMENT Continuation of evidence that estrogen may offer some degree of protection in Alzheimer's disease. rpm2 0 ...

Richard Mayeux on Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease.

COMMENT These add strong support to the notion that therapy targeting amyloid-beta may be an effective treatment for Alzheimer's disease. rpm2 0 ...

Richard Mayeux on Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis.

COMMENT Potential source for amyloid binding at the cellular level. rpm2 0 ...

Richard Mayeux on Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease.

COMMENT Timing is everything. This study suggests that COX2 may be upregulated in AD (assuming that animal models are an accurate reflection of the disease) at later stages in the pathogenesis of the disease. Thus, inhibitors of COX2 might be more useful in ...